Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin Pharmaceutical Mr. Cooper is a former independent director of Sierra Oncology, acquired by GlaxoSmithKline for $1.9 billion in 2022 and Tobira Therapeutics, acquired by Allergan (now […]
Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors
Dr. Coleman joins the Nexcella, Inc. Board of Directors with over a decade of experience as an Independent Director of Johnson & Johnson from 2003-2016 Dr. Coleman is President Emerita of the University of Michigan where she was named one of “10 Best College Presidents” by TIME Magazine and served as President of the University […]
Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors
Dr. Coleman joins the Nexcella, Inc. Board of Directors with over a decade of experience as an Independent Director of Johnson & Johnson from 2003-2016 Dr. Coleman is President Emerita of the University of Michigan where she was named one of “10 Best College Presidents” by TIME Magazine and served as President of the University […]
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Participating institutional investors include Bridgewest Group LOS ANGELES, June 14, 2023 — Immix Biopharma, Inc., (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering CAR-T cell therapies and tissue specific therapeutics targeting oncology and immuno-dysregulated diseases, today announced that it has completed its previously announced “at-the-market” equity offering program (the “ATM Offering”). “We are […]
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Participating institutional investors include Bridgewest Group LOS ANGELES, June 14, 2023 — Immix Biopharma, Inc., (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering CAR-T cell therapies and tissue specific therapeutics targeting oncology and immuno-dysregulated diseases, today announced that it has completed its previously announced “at-the-market” equity offering program (the “ATM Offering”). “We are […]
Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive Officer Dr. McKinnell is a former independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022 and former Chairman/CEO of Optimer Pharmaceuticals, acquired by Cubist (now Merck & […]
Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive Officer Dr. McKinnell is a former independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022 and former Chairman/CEO of Optimer Pharmaceuticals, acquired by Cubist (now Merck & […]
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring the Company’s existing CAR-T GMP manufacturing process to the United States Commencement of U.S. engineering batches follows selection of U.S. GMP manufacturer in February 2023 LOS ANGELES, May […]
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring the Company’s existing CAR-T GMP manufacturing process to the United States Commencement of U.S. engineering batches follows selection of U.S. GMP manufacturer in February 2023 LOS ANGELES, May […]
Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS 62% (5/8) had NYHA classification III or IV heart failure prior to treatment with NXC-201 Best responder duration of […]